Genome-Edited Cell-Derived Peptide Signatures as Biomarkers of Therapeutic Product Identity

Abstract

Genome-edited cellular therapeutics have transformed the landscape of precision medicine. However, ensuring the consistent identity, purity, and potency of these complex products remains a significant challenge, especially as they transition from bench to bedside. Peptide signatures derived from genome-edited cells are emerging as highly specific biomarkers for therapeutic product identity. This review explores the scientific principles, clinical implications, and regulatory perspectives of using genome-edited cell-derived peptide signatures as robust biomarkers, with a focus on their utility in quality control, batch verification, and patient safety.

Introduction

Recent advances in genome editing technologies, such as CRISPR/Cas9, have facilitated the development of next-generation cell-based therapies for a range of diseases, including hematologic malignancies, genetic disorders, and autoimmune conditions. As these therapies progress through clinical translation, there is a growing need for reliable, reproducible, and specific biomarkers that can accurately distinguish therapeutic products, authenticate their cellular origin, and monitor their stability throughout manufacturing and clinical application. Peptide signatures unique proteomic fingerprints resulting from the genome editing process offer a promising approach to address these challenges, providing molecular-level assurance of product identity for clinicians, researchers, and regulatory authorities.

Epidemiology / Disease Burden

The global burden of diseases amenable to genome-edited cellular therapies is substantial. Hematologic malignancies, such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and multiple myeloma, affect hundreds of thousands annually. Monogenic disorders, including sickle cell disease and thalassemias, remain incurable for many without cellular interventions. The increasing prevalence of autoimmune and degenerative diseases further amplifies the demand for novel, curative treatment modalities. As clinical trials for genome-edited cell therapies expand worldwide, the need for standardized biomarkers to ensure product integrity, traceability, and consistency grows in parallel, ultimately influencing clinical outcomes and patient safety.

Pathophysiology

Genome editing introduces precise alterations in cellular DNA, resulting in targeted protein changes that can correct disease-causing mutations, enhance immune cell function, or confer resistance to pathological processes. These DNA modifications are transcribed and translated into novel or altered peptides, collectively forming a distinct peptide signature unique to each edited cell line. The presence, abundance, and sequence characteristics of these peptides can be detected and quantified using mass spectrometry and advanced proteomics platforms, directly reflecting the genomic edits and their biological consequences. Thus, peptide signatures serve as real-time, mechanistically linked biomarkers of therapeutic manipulation, capturing both intended and off-target effects at the molecular level.

Risk Factors

Risks associated with the use of genome-edited cellular products include off-target genetic effects, clonal heterogeneity, immunogenicity, and loss of intended therapeutic function. Variability during manufacturing, storage, or transport can further affect product consistency. Inadequate product identification or batch mislabeling may lead to serious adverse events, including administration errors, reduced efficacy, or unintended immune reactions. The implementation of robust peptide signature-based assays can mitigate these risks by enabling precise product authentication and early detection of deviations from standard manufacturing protocols.

Clinical Features

In the clinical context, genome-edited cell therapies are typically characterized by their disease-modifying potential, durable responses, and, in some cases, curative outcomes. However, their safety and efficacy profiles are intimately tied to the quality and identity of the administered product. Variations in peptide signatures can correlate with changes in cell phenotype, potency, and functional characteristics, which may manifest clinically as differences in therapeutic response, risk of relapse, or adverse events. Therefore, continuous monitoring of peptide biomarkers during and after therapy can inform clinical decision-making, support pharmacovigilance, and facilitate individualized patient care.

Diagnosis

Diagnosis of product identity for genome-edited cell therapies relies on a combination of genomic, transcriptomic, and proteomic analyses. Peptide signature profiling, typically performed via liquid chromatography-tandem mass spectrometry (LC-MS/MS), provides high specificity and sensitivity for detecting unique post-editing proteomic changes. These methods enable batch-to-batch comparison, detection of unintended modifications, and confirmation of cell lineage. Integration with orthogonal assays such as flow cytometry, qPCR, and next-generation sequencing enhances diagnostic accuracy, ensuring that only correctly edited and characterized products reach clinical use.

Treatment & Management

The clinical management of patients receiving genome-edited cell therapies involves multidisciplinary coordination, rigorous pre-infusion quality checks, and ongoing monitoring for efficacy and adverse effects. Peptide signature assays are integrated into the release criteria for therapeutic products, serving as a gatekeeper for lot approval and clinical administration. In cases of suspected product contamination, mislabeling, or loss of function, rapid peptide analysis can guide product recall, reinfusion decisions, or changes in patient management protocols. Additionally, real-time peptide monitoring post-infusion may offer insights into engraftment, persistence, and in vivo performance of therapeutic cells.

Recent Advances / Emerging Therapies

Recent innovations in proteomics, artificial intelligence, and machine learning have enabled the development of highly multiplexed peptide signature panels capable of discriminating between closely related cell lines and detecting minute variations in product composition. Integration of peptide biomarkers with digital manufacturing records and blockchain technology further enhances traceability and regulatory compliance. Emerging therapies, including allogeneic off-the-shelf CAR-T cells, gene-corrected hematopoietic stem cells, and organoid-based treatments, are increasingly adopting peptide signature validation as part of their standard quality assurance workflow. These advances are accelerating the transition of genome-edited cellular products from experimental to mainstream clinical practice.

Guideline Recommendations

Regulatory agencies, including the FDA, EMA, and international harmonization committees, have issued draft guidelines emphasizing the importance of identity testing and quality control for advanced therapy medicinal products (ATMPs). Incorporation of peptide signature-based assays is recommended for both investigational and licensed products, given their ability to provide unambiguous, mechanism-based evidence of product identity. Multidisciplinary collaboration between clinicians, laboratory scientists, and regulatory experts is essential to standardize assay protocols, define acceptance criteria, and ensure robust validation of peptide biomarkers in clinical and manufacturing settings.

Conclusion

Genome-edited cell-derived peptide signatures represent a transformative advance in the authentication and quality assurance of cellular therapeutics. By providing a direct molecular link between genome editing events and product identity, peptide biomarkers contribute to enhanced safety, efficacy, and regulatory compliance in clinical practice. As the field continues to evolve, the integration of peptide signature analysis with emerging technologies and standardized guidelines will be pivotal in realizing the full potential of genome-edited cell therapies for a wide spectrum of diseases.